Phase 3 multi-site double-blind randomized forced titration parallel group evaluation of the efficacy safety and tolerability of fixed combination torcetrapib (Cp 529 414)/atorvastatin administered orally, once daily (qd) for eighteen weeks, compared with atorvastatin alone in subjects with Fredrickson type IV hypertriglyceridemia

Trial Profile

Phase 3 multi-site double-blind randomized forced titration parallel group evaluation of the efficacy safety and tolerability of fixed combination torcetrapib (Cp 529 414)/atorvastatin administered orally, once daily (qd) for eighteen weeks, compared with atorvastatin alone in subjects with Fredrickson type IV hypertriglyceridemia

Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2006

At a glance

  • Drugs Atorvastatin; Torcetrapib/atorvastatin
  • Indications Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 05 Dec 2006 Status change
    • 17 Oct 2006 Status change
    • 06 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top